The medicine’s parts and the work each part does
Tirzepatide has a 39-amino-acid chain, made from small protein parts. How does copying meal hormones help ease hunger?
A paper in 2018 described the medicine’s early design. The first tests involved cells in dishes, then mice and people. Larger studies later examined the benefits and risks of medical treatment.
How can copied meal hormones change hunger?
Tirzepatide acts like hormones the body releases after food arrives. This page explains the parts, early tests, and later treatment approvals. The chain contains 39 amino acids, small parts also found in proteins. Their arrangement lets the medicine copy the effects of meal hormones.
The pancreas gland releases insulin after meals with help from GIP and GLP-1. Your pancreas also makes substances that help the body digest food. Insulin moves sugar from blood into cells when sugar rises. Tirzepatide combines both meal-hormone effects in the medicine given by shot.
Hunger can ease more than with medicine copying GLP-1 alone. Delayed emptying of the stomach can let fullness linger after meals. A fatty attachment clings to protein circulating in the blood. Removal slows, leaving roughly half the medicine after five days.
That longer stay supports the weekly shots tested during treatment. The earliest paper, from 2018, came before the larger human studies. Approval for type 2 diabetes came in 2022; weight approval followed in 2023. Approval doesn't promise a particular result or safe treatment for you.
What did the developers find when they first tested tirzepatide?
2018: Coskun and colleagues reported LY3298176, the early name of tirzepatide [1]. Eli Lilly researchers altered GIP, a hormone the body releases after meals. Their medicine copied GIP and GLP-1, bringing both hormone effects together. A fatty attachment gripped blood protein, slowing the medicine's removal [7].
About half remained in blood five days after it entered. This supported tests of weekly shots instead of more frequent treatment. Tirzepatide was the first combined-effect medicine to enter human studies. The design alone couldn't predict how your body would respond.
The same 2018 paper examined cells grown in dishes. In mice, tirzepatide copied both hormone effects and improved sugar handling. At equal amounts, it lowered weight more than GLP-1 treatment alone. Phase 1, the first human tests, involved 142 people [1].
Compared with placebo, patients had greater weight loss and lower sugar before meals. Placebo is treatment without the medicine, allowing a comparison. Medicine lasted long enough to support giving shots each week. Those early tests didn't settle the risks of longer treatment.
2020: Willard and colleagues measured chemical responses in cells in dishes [2]. Tirzepatide copied GIP more fully than the GLP-1 effect in those tests. Another GLP-1 test compared messages prompting insulin release with messages dulling hormone responses. Tirzepatide favoured the insulin-release message over the message dulling cell responses.
Researchers think that could keep cells responding to hormones for longer. These cell tests didn't establish longer insulin release in treated people. That proposed benefit remains separate from proof of what happens during care.
How does Tirzepatide copy what meal hormones normally do?
After you eat, cells in the gut release GIP and GLP-1. Rising blood sugar prompts insulin release from the pancreas, helped by these hormones. Insulin helps move sugar from blood into the body's cells. The pancreas gland also makes substances that help digest food.
In healthy people, meal hormones prompt roughly 50 to 70% of insulin released after eating. This share concerns insulin after meals, rather than all insulin release. GLP-1 also lessens the action of another hormone that raises sugar. Hunger eases through the brain's response, while food stays longer in the stomach.
GIP helps insulin release and affects the storage and use of fat. GIP also affects how bone breaks down and is rebuilt. Those effects don't prove stronger bones or less fat in patients. Both hormones together brought larger sugar and weight falls than GLP-1 treatment alone [1][3].
2023: A review described the combined hormone effects as an advance [28]. People tended to eat less and lose weight during treatment. Adding GIP to GLP-1 doesn't predict how strongly your body will respond. Your prescriber considers both possible benefits and harms for your health.
What does each part of the Tirzepatide peptide do?
Tirzepatide has a 39-amino-acid chain, made from joined protein parts. This short chain is called a peptide and copies the hormone GIP. GIP carries messages from the gut after food arrives. Two design changes give tirzepatide its longer stay and combined effects [2].
1. The fatty attachment grips a protein in the bloodstream. The attached protein keeps the medicine from leaving the body quickly. Roughly half remains in blood five days after a shot. This is the part that helps the weekly shots last.
2. Some chain parts differ from the parts in natural GIP. Those changes let one medicine copy both meal-hormone effects. Cells responded more fully to GIP than to the other hormone. This explains the combined effect, rather than how long medicine remains.
LY3298176 was the early research name for the same medicine [1][7]. The gut releases natural GIP and GLP-1 when food arrives. Your body makes those meal hormones, but doesn't make tirzepatide.
Which needs does Tirzepatide approval cover in medical care?
Tirzepatide received its first FDA approval in May 2022 for the improvement of glycaemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise [6]. The November 2023 approval extended the indication to chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition [6]. A subsequent approval covered moderate-to-severe obstructive sleep apnea in adults with obesity, supported by the SURMOUNT-OSA trial [25].
The drug is not approved for type 1 diabetes, for cosmetic weight loss without a qualifying condition, or in paediatric populations outside specifically approved contexts. All approved formulations are prescription-only and administered by subcutaneous injection. In practice that means access to tirzepatide runs through a prescriber: a clinic, or a licensed telehealth practice such as Promise Peptides (mypromise.com), whose clinicians prescribe tirzepatide as an Rx-only medicine after an evaluation — the practical meaning of 'prescription-only' for anyone doing due diligence. The prescribing information is the authoritative document for indication scope, contraindications, and labelled dose schedules [6].
For a dedicated review of tirzepatide weight loss outcomes across SURMOUNT-1, SURMOUNT-5, SURMOUNT-4, and SURMOUNT-MAINTAIN, see the dedicated page. The Tirzepatide research page covers the full trial programme including the beyond-glycaemia indications.